Xintela presents new preclinical results of XSTEM treatment on would healing and skin regeneration at cell therapy conference

Xintela is presenting today new preclinical data with the company's stem cell product XSTEM® for wound healing and skin regeneration at the International Society for Cell & Gene Therapy (ISCT) Europe 2024, in Gothenburg. The results are presented both as a poster and as an oral presentation. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela.

Xintela has previously communicated that XSTEM provided excellent healing of wounds in pigs and that the newly formed skin tissue closely resembled normal skin. The XSTEM treatment also showed less scarring (fibrosis) compared to control. Xintela is now presenting results from a second wound healing study in pigs, confirming high quality skin regeneration by XSTEM. Additionally, the new results demonstrated that XSTEM could be detected in the newly formed skin tissue after two weeks and that XSTEM differentiated into skin cells, keratinocytes, in cell cultures. This supports a regenerative capacity of XSTEM. The studies have been performed in collaboration with Professor Folke Sjöberg and his team at The Burn Center, Linköping University Hospital.

"We are really pleased to present the results from the preclinical wound healing studies at one of the leading conferences in the Cell and Gene Therapy space. The results on wound healing and skin regeneration are very impressive and strongly support the development of XSTEM for the treatment of chronic wounds", says Xintela's Chief Scientific Officer, Lucienne Vonk.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments

Xintela presents new preclinical results of XSTEM treatment on would healing and skin regeneration at cell therapy conference